144 related articles for article (PubMed ID: 17924988)
1. Chronic acid-base perturbations in hemodialysis patients treated with sevelamer hydrochloride: a two-year follow-up study.
Vlahakos DV; Retsa K; Kalogeropoulou S; Katsoudas S; Bacharaki D; Agroyannis B
Artif Organs; 2007 Dec; 31(12):892-5. PubMed ID: 17924988
[TBL] [Abstract][Full Text] [Related]
2. Sevelamer worsens metabolic acidosis in hemodialysis patients.
De Santo NG; Frangiosa A; Anastasio P; Marino A; Correale G; Perna A; Di Stazio E; Stellato D; Santoro D; Di Meglio E; Iacono G; Ciacci C; Savica V; Cirillo M
J Nephrol; 2006; 19 Suppl 9():S108-14. PubMed ID: 16736432
[TBL] [Abstract][Full Text] [Related]
3. Influence of sevelamer on mineral metabolism and hyperparathyroidism in Japanese hemodialysis patients.
Inoue T; Nagatoya K; Kagitani M; Shibahara N; Ueda H; Katsuoka Y; Ohashi S; Kitagawa Y; Nishimoto K; Yasuda H;
Ther Apher Dial; 2007 Jun; 11(3):210-4. PubMed ID: 17498003
[TBL] [Abstract][Full Text] [Related]
4. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
[TBL] [Abstract][Full Text] [Related]
5. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients.
Yamada K; Fujimoto S; Tokura T; Fukudome K; Ochiai H; Komatsu H; Sato Y; Hara S; Eto T
Ren Fail; 2005; 27(4):361-5. PubMed ID: 16060120
[TBL] [Abstract][Full Text] [Related]
6. Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines.
Nolan CR
Kidney Int Suppl; 2005 Jul; (96):S7-14. PubMed ID: 15954948
[TBL] [Abstract][Full Text] [Related]
7. Long-term management of sevelamer hydrochloride-induced metabolic acidosis aggravation and hyperkalemia in hemodialysis patients.
Sonikian M; Metaxaki P; Iliopoulos A; Marioli S; Vlassopoulos D
Ren Fail; 2006; 28(5):411-8. PubMed ID: 16825091
[TBL] [Abstract][Full Text] [Related]
8. Metabolic acidosis aggravation and hyperkaliemia in hemodialysis patients treated by sevelamer hydrochloride.
Sonikian MA; Pani IT; Iliopoulos AN; Koutala KG; Marioli SI; Vlassopoulos DA
Ren Fail; 2005; 27(2):143-7. PubMed ID: 15807177
[TBL] [Abstract][Full Text] [Related]
9. [How to reach and maintain the K/DOQI recommendations for bone and mineral metabolism in patients undergoing haemodialysis: an efficient strategy].
Rottembourg J; Diab R; Boulechfar H
Nephrol Ther; 2007 Mar; 3(1):33-42. PubMed ID: 17383589
[TBL] [Abstract][Full Text] [Related]
10. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial.
Suki WN;
J Ren Nutr; 2008 Jan; 18(1):91-8. PubMed ID: 18089452
[TBL] [Abstract][Full Text] [Related]
11. Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage.
Oka Y; Miyazaki M; Takatsu S; Kunitomo K; Uno F; Maruyama M; Matsuda H
Ther Apher Dial; 2007 Apr; 11(2):107-13. PubMed ID: 17381531
[TBL] [Abstract][Full Text] [Related]
12. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
Pai AB; Shepler BM
Pharmacotherapy; 2009 May; 29(5):554-61. PubMed ID: 19397463
[TBL] [Abstract][Full Text] [Related]
13. Buffering effects of calcium carbonate as clarified by sevelamer hydrochloride monotherapy.
Akatsuka T; Mochizuki T; Koike T
Ther Apher Dial; 2008 Jun; 12(3):216-25. PubMed ID: 18503699
[TBL] [Abstract][Full Text] [Related]
14. [Clinical analysis of time-course changes in minerals and parathyroid hormone levels during treatment with phosphate binders in hemodialysis patients with secondary hyperparathyroidism].
Yokoyama T; Onodera Y; Mano T
Clin Calcium; 2005 Sep; 15 Suppl 1():125-30; discussion 130-1. PubMed ID: 16272644
[TBL] [Abstract][Full Text] [Related]
15. [Defining the role of sevelamer chloride as a therapeutic agent for management of phosphate in patient with hemodialysis].
Hashimoto N; Miyata M; Sato N; Mochizuki T; Koike T
Clin Calcium; 2005 Sep; 15 Suppl 1():30-4; discussion 34. PubMed ID: 16272626
[TBL] [Abstract][Full Text] [Related]
16. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan.
Koiwa F; Onoda N; Kato H; Tokumoto A; Okada T; Fukagawa M; Shigematsu T;
Ther Apher Dial; 2005 Aug; 9(4):340-6. PubMed ID: 16076379
[TBL] [Abstract][Full Text] [Related]
17. [Treatment with phosphate binder (sevelamer hydrochloride, calcium carbonate) based on PTH].
Sato M; Fukazawa S; Yasuda T; Akatsuka T; Tozawa S; Niida Y; Hashimoto N; Mochizuki T; Koike T
Clin Calcium; 2005 Sep; 15 Suppl 1():23-8; discussion 28-9. PubMed ID: 16272625
[TBL] [Abstract][Full Text] [Related]
18. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients.
Hamida FB; Fatma LB; Barbouch S; Kaaroud H; Helal I; Hedri H; Abdallah TB; Maiz HB; Kheder A
Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):183-8. PubMed ID: 18310864
[TBL] [Abstract][Full Text] [Related]
19. Association between C-reactive protein and biomarkers of bone and mineral metabolism in chronic hemodialysis patients: a cross-sectional study.
Lee CT; Tsai YC; Ng HY; Su Y; Lee WC; Lee LC; Chiou TT; Liao SC; Hsu KT
J Ren Nutr; 2009 May; 19(3):220-7. PubMed ID: 19243976
[TBL] [Abstract][Full Text] [Related]
20. Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study.
Sun PP; Perianayagam MC; Jaber BL
J Ren Nutr; 2009 Sep; 19(5):432-8. PubMed ID: 19464926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]